AtriCure Inc. ATRC shares are trading higher by 6.35% at $69.03 after the company reported better-than-expected first-quarter EPS and sales results.
Oppenheimer analyst Suraj Kalia maintains AtriCure with an Outperform and raises the price target from $65 to $75.
Needham analyst Mike Matson also maintains AtriCure with a Buy and raises the price target from $74 to $81.
AtriCure is an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
